Anticonvulsants in bipolar disorder

Journal of Mental Health

Volumn 19, Issue 2, 2010, Pages 127-141

  Grunze, Heinz C R ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Anticonvulsants; Bipolar disorder; Depression; Mania; Psychosis

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; BIOGENIC AMINE; CARBAMAZEPINE; CATECHOLAMINE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; DEXAMPHETAMINE; DOPAMINE; HYDROCORTISONE; INDOLEAMINE; LAMOTRIGINE; SEROTONIN; VALPROIC ACID; VIGABATRIN;

ANTICONVULSANT ACTIVITY; BIPOLAR DISORDER; BRAIN FUNCTION; DISEASE COURSE; DISEASE MODEL; DNA DAMAGE; DRUG MECHANISM; GABAERGIC SYSTEM; HORMONE BLOOD LEVEL; HUMAN; MANIA; MENTAL STRESS; NONHUMAN; OXIDATIVE STRESS; RECURRENT DISEASE; REVIEW;

ANTICONVULSANTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; HUMANS;

EID: 77950819930     PISSN: 09638237     EISSN: 13600567     Source Type: Journal    
DOI: 10.3109/09638230903469186     Document Type: Review

References (140)

1. Altshuler, L.L., Keck, P.E., McElroy, S.L., Suppes, T., Brown, E.S., Denicoff, K. et al. (1999). Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disorders, 1, 61-65.
2. Amann, B., Sterr, A., Vieta, E., Stampfer, R., Walden, J., & Grunze, H. (2006). An exploratory open trial on safety and efficacy of the anticonvulsant retigabine in acute manic patients. Journal of Clinical Psychopharmacology, 26, 534-536.
3. Anand, A., Bukhari, L., Jennings, S.A., Lee, C., Kamat, M., Shekhar, A.et al. (2005). A preliminary open-label study of zonisamide treatment for bipolar depression in 10 patients. Journal of Clinical Psychiatry, 66, 195-198.
4. Andreasen, A.H., Brosen, K., & Damkier, P. (2007). A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. Epilepsia, 48, 490-496.
5. Andreazza, A.C., Kauer-Sant'Anna, M., Frey, B.N., Stertz, L., Zanotto, C., Ribeiro, L. et al. (2008). Effects of mood stabilizers on DNA damage in an animal model of mania. Journal of Psychiatry & Neuroscience, 33, 516-524.
6. +,K(+)-ATPase pump numbers in lymphocytes from the first-degree unaffected relatives of patients with manic depressive psychosis in response to in vitro lithium and sodium ethacrynate. Journal of Affective Disorders, 34, 33-39.
7. Bachmann, R.F., Schloesser, R.J., Gould, T.D., & Manji, H.K. (2005). Mood stabilizers target cellular plasticity and resilience cascades: Implications for the development of novel therapeutics. Molecular Neurobiology, 32, 173-202.
8. Basselin, M., Chang, L., Chen, M., Bell, J.M., & Rapoport, S.I. (2008). Chronic administration of valproic acid reduces brain NMDA signaling via arachidonic acid in unanesthetized rats. Neurochemistry Research, 33, 2229-2240.
9. Basselin, M., Villacreses, N.E., Chen, M., Bell, J.M., & Rapoport, S.I. (2007). Chronic carbamazepine administration reduces N-methyl-D-aspartate receptor-initiated signaling via arachidonic acid in rat brain. Biological Psychiatry, 62, 934-943.
10. Berridge, M.J., & Irvine, R.F. (1989). Inositol phosphates and cell signalling. Nature, 341, 197-205.
11. Bersudsky, Y. (2006). Phenytoin: An anti-bipolar anticonvulsant? International Journal of Neuropsychopharmacology, 9, 479-484.
12. Bowden, C., Gogus, A., Grunze, H., Haggstrom, L., Rybakowski, J., & Vieta, E. (2008). A 12-week, open, randomized trial comparing sodium valproate to lithium in patients with bipolar I disorder suffering from a manic episode. International Journal of Clinical Psychopharmacology, 23, 254-262.
13. Bowden, C.L., Brugger, A.M., Swann, A.C., Calabrese, J.R., Janicak, P.G., Petty, F. et al. (1994). Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. Journal of the American Medical Association, 271, 918-924.
14. Bowden, C.L., Swann, A.C., Calabrese, J.R., Rubenfaer, L.M., Wozniak, P.J., Collins, M.A. et al. (2006). A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. Journal of Clinical Psychiatry, 67, 1501-1510.
15. Brown, D., Silverstone, T., & Cookson, J. (1989). Carbamazepine compared to haloperidol in acute mania. International Journal of Clinical Psychopharmacology, 4, 229-238.
16. Brown, E.B., McElroy, S.L., Keck, P.E., Jr., Deldar, A., Adams, D.H., Tohen, M. et al. (2006). A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. Journal of Clinical Psychiatry, 67, 1025-1033. (Pubitemid 44230872)
17. Buki, V.M., & Goodnick, P. (1998). Catecholamines. In P. Goodnick (Ed.), Mania. Clinical and research perspectives (pp. 119-134). Washington, DC: APA Press.
18. Calabrese, J.R., Bowden, C.L., Sachs, G.S., Ascher, J.A., Monaghan, E., Rudd G. et al. (1999). A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Journal of Clinical Psychiatry, 60, 79-88.
19. Carta, M.G., Hardoy, M.C., Grunze, H., & Carpiniello, B. (2002). The use of tiagabine in affective disorders. Pharmacopsychiatry, 35, 33-34.
20. Chen, C., Glatt, S.J., & Tsuang, M.T. (2008). The tryptophan hydroxylase gene influences risk for bipolar disorder but not major depressive disorder: Results of meta-analyses. Bipolar Disorders, 10, 816-821.
21. Chen, G., Huang, L.D., Jiang, Y.M., & Manji, H.K. (1999). The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. Journal of Neurochemistry, 72, 1327-1330.
22. Chen, G., Huang, L.D., Zeng, W.Z., & Manji, H.K. (2001). Mood stabilizers regulate cytoprotective and mRNAbinding proteins in the brain: Long-term effects on cell survival and transcript stability. International Journal of Neuropsychopharmacology, 4, 47-64.
23. Chen, G., & Manji, H.K. (2006). The extracellular signal-regulated kinase pathway: An emerging promising target for mood stabilizers. Current Opinion in Psychiatry, 19, 313-323.
24. Chen, P.S., Peng, G.S., Li, G., Yang, S., Wu, X., Wang, C.C. et al. (2006). Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Molecular Psychiatry, 11, 1116-1125.
25. Choi, H., & Morrell, M.J. (2003). Review of lamotrigine and its clinical applications in epilepsy. Expert Opinion in Pharmacotherapy, 4, 243-251.
26. Craddock, N., Jones, L., Jones, I.R., Kirov, G., Green, E.K., Grozeva, D., Moskvina, V., Nikolov, I., Hamshere, M.L., Vukcevic, D., Caesar, S., Gordon-Smith, K., Fraser, C, Russell, E., Norton, N., Breen, G., St, C.D., Collier, D.A., Young, A.H., Ferrier, I.N., Farmer, A., McGuffin, P., Holmans, P.A., Donnelly, P., Owen, M.J., & O'Donovan, M.C. (2010). Strong genetic evidence for a selective influence of GABA(A) receptors on a component of the bipolar disorder phenotype. Molecular Psychiatry, 15, 146-153.
27. Dailey, J.W., Reith, M.E., Yan, Q.S., Li, M.Y., & Jobe, P.C. (1997). Carbamazepine increases extracellular serotonin concentration: lack of antagonism by tetrodotoxin or zero Ca2+. European Journal of Pharmacology, 328, 153-162.
28. Davis, L.L., Bartolucci, A., & Petty, F. (2005). Divalproex in the treatment of bipolar depression: A placebocontrolled study. Journal of Affective Disorders, 85, 259-266.
29. De Marcos, F.A., Ghizoni, E., Kobayashi, E., Li, L.M., & Cendes, F. (2003). Cerebellar volume and long-term use of phenytoin. Seizure, 12, 312-315.
30. Denicoff, K.D., Smith-Jackson, E.E., Disney, E.R., Ali, S.O., Leverich, G.S., & Post, R.M. (1997). Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. Journal of Clinical Psychiatry, 58, 470-478.
31. Diehl, D.J., & Gershon, S. (1992). The role of dopamine in mood disorders. Comprehensive Psychiatry, 33, 115-120.
32. Dubovsky, S.L., & Franks, R.D. (1983). Intracellular calcium ions in affective disorders: A review and an hypothesis. Biological Psychiatry, 18, 781-797.
33. Emrich, H.M. & Wolf, R. (1992). Valproate treatment of mania. Progress in Neuropsychopharmacology & Biological Psychiatry, 16, 691-701.
34. Farber, N.B., Jiang, X.P., Heinkel, C., & Nemmers, B. (2002). Antiepileptic drugs and agents that inhibit voltagegated sodium channels prevent NMDA antagonist neurotoxicity. Molecular Psychiatry, 7, 726-733.
35. Freeman, T.W., Clothier, J.L., Pazzaglia, P., Lesem, M.D., & Swann, A.C. (1992). A double-blind comparison of valproate and lithium in the treatment of acute mania. American Journal of Psychiatry, 149, 108-111.
36. Frye, M., Ketter, T., Kimbrell, T.A., Dunn, R., Speer, A., Osuch, E. et al. (2000). A placebo controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. Journal of Clinical Psychopharmacology, 20, 607-614.
37. Gajwani, P., Forsthoff, A., Muzina, D., Amann, B., Gao, K., Elhaj, O. et al. (2005). Antiepileptic drugs in mooddisordered patients. Epilepsia, 46 (Suppl. 4), 38-44.
38. Gallagher, P., Reid, K.S., & Watson, S. (2006). Phenytoin, an anti-bipolar anticonvulsant: a potential antiglucocorticoid mechanism? International Journal of Neuropsychopharmacology, 9, 627-628.
39. Geddes, J. (2003). Efficacy and safety of electroconvulsive therapy in depressive disorders: A systematic review and meta-analysis. Lancet, 361, 799-808.
40. Ghaemi, S.N., Gilmer, W.S., Goldberg, J.F., Zablotsky, B., Kemp, D.E., Kelley, M.E. et al. (2007). Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. Journal of Clinical Psychiatry, 68, 1840-1844.
41. Ghaemi, S.N., Zablotsky, B., Filkowski, M.M., Dunn, R.T., Pardo, T.B., Isenstein, E. et al. (2006). An open prospective study of zonisamide in acute bipolar depression. Journal of Clinical Psychopharmacology, 26, 385-388.
42. Goldberg, J.F., & Burdick, K.E. (2002). Levetiracetam for acute mania. American Journal of Psychiatry, 159, 148.
43. Goldberg, J.F., Garno, J.L., & Harrow, M. (2005). Long-term remission and recovery in bipolar disorder: A review. Current Psychiatry Reports, 7, 456-461.
44. Goldberg, J.F., & Harrow, M. (1994). Kindling in bipolar disorders: A longitudinal follow-up study. Biological Psychiatry, 35, 70-72.
45. Goodwin, F.K., & Jamison, K.R. (2007). Manic -depressive illness, 2nd edn. New York: Oxford University Press.
46. Goodwin, G.M., Bowden, C.L., Calabrese, J.R., Grunze, H., Kasper, S., White, R. et al. (2004). A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in Bipolar I disorder. Journal of Clinical Psychiatry, 65, 432-441.
47. Granger, P., Biton, B., Faure, C., Vige, X., Depoortere, H., Graham, D. et al. (1995). Modulation of the gammaaminobutyric acid type A receptor by the antiepileptic drugs carbamazepine and phenytoin. Molecular Pharmacology, 47, 1189-1196.
48. Greil, W., Kleindienst, N., Erazo, N., & Mü ller-Oerlinghausen, B. (1998). Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. Journal of Clinical Psychopharmacology, 18, 455-460.
49. Greil, W., Ludwig-Mayerhofer, W., Erazo, N., Schö chlin, C., Schmidt, S., Engel, R.R. et al. (1997). Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study. Journal of Affective Disorders, 43, 151-161. (Pubitemid 27219568)
50. Grunze, H., Erfurth, A., Marcuse, A., Amann, B., Normann, C., & Walden, J. (1999). Tiagabine appears not to be efficacious in the treatment of acute mania. Journal of Clinical Psychiatry, 60, 759-762.
51. Grunze, H., Greene, R.W., Mö ller, H.-J., Meyer, T., & Walden, J. (1998). Lamotrigine may limit pathological excitation in the hippocampus by modulating a transient potassium outward current. Brain Research, 791, 330-334.
52. Grunze, H., Langosch, J., Born, C., Schaub, G., & Walden, J. (2003). Levetiracetam in the treatment of acute mania: An open add-on study with an on-off-on design. Journal of Clinical Psychiatry, 64, 781-784.
53. Grunze, H., Schü le, C., Casey, D.E., & Baghai, T.C. (2008). Mood disorders: Depression. In A. Tasman, M. Maj, M.B. First, J. Kay, & J.A. Lieberman (Eds.), Psychiatry (3rd edn, pp. 1283-1320). Chichester: Wiley and Sons.
54. Grunze, H., Vieta, E., Goodwin, G.M., Bowden, C., Licht, R.W.,Moller, H.J. et al. (2009). The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2009 on the treatment of acute mania. World Journal of Biological Psychiatry, 10, 85-116.
55. Harkin, A., Kelly, J.P., & Leonard, B.E. (2006). A review of the relevance and validity of olfactory bulbectomy as a model of depression. Clinical Neuroscience Research, 3, 253-262.
56. Hartong, E.G., Moleman, P., Hoogduin, C.A., Broekman, T.G., & Nolen, W.A. (2003). Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. Journal of Clinical Psychiatry, 64, 144-151.
57. Jensen, J.B., & Mork, A. (1997). Altered protein phosphorylation in the rat brain following chronic lithium and carbamazepine treatments. European Neuropsychopharmacology, 7, 173-179.
58. Jezova, D. (2005). Control of ACTH secretion by excitatory amino acids: functional significance and clinical implications. Endocrine, 28, 287-294.
59. Kanba, S., Yagi, G., Kamijima, K., Suzuki, T., Tajima, O., Otaki, J. et al. (1994). The first open study of zonisamide, a novel anticonvulsant, shows efficacy in mania. Progress in Neuropsychopharmacology & Biological Psychiatry, 18, 707-715.
60. Kasperlik-Zaluska, A.A., Zgliczynski, W., Jeske, W., & Zdunowski, P. (2005). ACTH responses to somatostatin, valproic acid and dexamethasone in Nelson's syndrome. Neuroendocrinology Letters, 26, 709-712.
61. Kassir, S., & Meltzer, H.L. (1991). Abnormal sensitivity of erythrocyte membrane Na/K ATPase of bipolar subjects to inhibition by calmodulin and calcium. Biological Psychiatry, 30, 631-634.
62. Kaster, M.P., Raupp, I., Binfare, R.W., Andreatini, R., & Rodrigues, A.L. (2007). Antidepressant-like effect of lamotrigine in the mouse forced swimming test: evidence for the involvement of the noradrenergic system. European Journal of Pharmacology, 565, 119-124.
63. Kaufman, R.E., Ostacher, M.J., Marks, E.H., Simon, N.M., Sachs, G.S., Jensen, J.E. et al. (2009). Brain GABA levels in patients with bipolar disorder. Progress in Neuropsychopharmacology & Biological Psychiatry, 33, 427-434.
64. Kraepelin, E. (1921a). Manic-depressive insanity and paranoia. Translated by R. Mary Barclay from the Eighth German Edition of the "Text-Book of Psychiatry", vol. iii, part ii, section on the Endogenous Dementias. Edinburgh: E. & S. Livingstone.
65. Kruger, S., Sarkar, R., Pietsch, R., Hasenclever, D., & Braunig, P. (2008). Levetiracetam as monotherapy or addon to valproate in the treatment of acute mania-a randomized open-label study. Psychopharmacology (Berl), 198, 297-299.
66. Kushner, S.F., Khan, A., Lane, R., & Olson, W.H. (2006). Topiramate monotherapy in the management of acute mania: results of four double-blind placebo-controlled trials. Bipolar Disorder, 8, 15-27.
67. Kyomen, H.H. (2006). The use of levetiracetam to decrease mania in elderly bipolar patients. American Journal of Geriatric Psychiatry, 14, 985.
68. Lambert, P.A., & Venaud, G. (1966). Utilisation de valpromide en therapeutique psychiatrique. L'encephale, 8, 367-373.
69. Lampe, H., & Bigalke, H. (1990). Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons. Neuroreport, 1, 26-28.
70. Lenox, R.H., & Watson, D.G. (1994). Lithium and the brain: A psychopharmacological strategy to a molecular basis for manic depressive illness. Clinical Chemistry, 40, 309-314.
71. Lisman, J. (1994). The CaM kinase II hypothesis for the storage of synaptic memory. Trends in Neuroscience, 17, 406-412.
72. Lö scher, W., & Hönack, D. (1996). Valproate and its major metabolite E-2-en-valproate induce different effects on behaviour and brain monoamine metabolism in rats. European Journal of Pharmacology, 299, 61-67.
73. Lubrich, B., & van Calker, D. (1999). Inhibition of the high affinity myo-inositol transport system: A common mechanism of action of antibipolar drugs? Neuropsychopharmacology, 21, 519-529.
74. Macdonald, R.L., & Kelly, K.M. (1993). Antiepileptic drug mechanisms of action. Epilepsia, 34(Suppl. 5), 1-8.
75. Maes, M., Calabrese, J., Jayathilake, K., & Meltzer, H.Y. (1997). Effects of subchronic treatment with valproate on L-5-HTP-induced cortisol responses in mania: evidence for increased central serotonergic neurotransmission. Psychiatry Research, 71, 67-76.
76. Manki, H., Kanba, S., Muramatsu, T., Higuchi, S., Suzuki, E., Matsushita, S., Ono, Y., Chiba, H., Shintani, F., Nakamura, M., Yagi, G., & Asai, M. (1996). Dopamine D2, D3 and D4 receptor and transporter gene polymorphisms and mood disorders. Journal of Affective Disorders, 40, 7-13.
77. McElroy, S.L., Keck, P.E., Stanton, S.P., Tugrul, K.C., Bennett, J.A., & Strakowski, S.M. (1996). A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. Journal of Clinical Psychiatry, 57, 142-146.
78. McElroy, S.L., Suppes, T., Keck, P.E., Jr., Black, D., Frye, M.A., Altshuler, L.L. et al. (2005). Open-label adjunctive zonisamide in the treatment of bipolar disorders: A prospective trial. Journal of Clinical Psychiatry, 66, 617-624.
79. McIntyre, R.S., Mancini, D.A., McCann, S., Srinivasan, J., Sagman, D., & Kennedy, S.H. (2002). Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: A preliminary single-blind study. Bipolar Disorders, 4, 207-213.
80. Mishory, A., Winokur, M., & Bersudsky, Y. (2003). Prophylactic effect of phenytoin in bipolar disorder: A controlled study. Bipolar Disorder, 5, 464-467.
81. Mishory, A., Yaroslavsky, Y., Bersudsky, Y., & Belmaker, R.H. (2000). Phenytoin as an antimanic anticonvulsant: A controlled study. American Journal of Psychiatry, 157, 463-465.
82. Moscovich, D.G., Belmaker, R.H., Agam, G., & Livne, A. (1990). Inositol-1-phosphatase in red blood cells of manic-depressive patients before and during treatment with lithium. Biological Psychiatry, 27, 552-555.
83. Mukherjee, S. (1989). Mechanisms of the Antimanic Effect of Electroconvulsive Therapy. Convulsive Therapy, 5, 227-243.
84. Mukherjee, S., Sackeim, H.A., & Schnur, D.B. (1994). Electroconvulsive therapy of acute manic episodes: A review of 50 years' experience. American Journal of Psychiatry, 151, 169-176.
85. Mü ller-Oerlinghausen, B., Retzow, A., Henn, F., Giedke, H., & Walden, J. (2000). Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania. A prospective, randomized, double- blind, placebo-controlled multicenter study. Journal of Clinical Psychopharmacology, 20, 195-203.
86. Muralidharan, A., & Bhagwagar, Z. (2006). Potential of levetiracetam in mood disorders: A preliminary review. CNS Drugs, 20, 969-979.
87. Naumann, M., Supprian, T., Kornhuber, J., Lange, K.W., & Reiners, K. (1994). Bipolar affective psychosis after vigabatrin. Lancet, 343, 606-607.
88. Nolen, W.A., Kupka, R.W., Hellemann, G., Frye, M.A., Altshuler, L.L., Leverich, G.S. et al. (2007). Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression: A failed but clinically useful study. Acta Psychiatrica Scandinavica, 115, 360-365.
89. Ogden, C.A., Rich, M.E., Schork, N.J., Paulus, M.P., Geyer, M.A., Lohr, J.B. et al. (2004). Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. Molecular Psychiatry, 9, 1007-1029.
90. Okuma, T., Kishimoto, A., Inoue, K., Matsumoto, H., & Ogura, A. (1973). Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report. Folia Psychiatrica Neurologia Japan, 27, 283-297.
91. Olpe, H., Kolb, C.N., Hausdorf, A., & Haas, H.L. (1991). 4-aminopyridine and barium chloride attenuate the antiepileptic effect of carbamazepine in hippocampal slices. Experientia, 47, 254-257.
92. Owen, R.T. (2006). Extended-release carbamazepine for acute bipolar mania: A review. Drugs Today (Barc), 42, 283-289.
93. Pande, A.C., Crockatt, J.G., Janney, C.A., Werth, J.L., & Tsaroucha, G. (2000). Gabapentin in bipolar disorder: a placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disorder, 2, 249-255.
94. Pope, H.G., McElroy, S.L., Keck, P.E., & Hudson, J.I. (1991). Valproate in the treatment of acute mania. A placebo-controlled study. Archives of General Psychiatry, 48, 62-68.
95. Popova, E., Leighton, C., Bernabarre, A., Bernardo, M., & Vieta, E. (2007). Oxcarbazepine in the treatment of bipolar and schizoaffective disorders. Expert Reviews in Neurotherapy, 7, 617-626.
96. Post, R.M., Ketter, T.A., Denicoff, K., Pazzaglia, P.J., Leverich, G.S., Marangell, L.B. et al. (1996). The place of anticonvulsant therapy in bipolar illness. Psychopharmacology, 128, 115-129.
97. Post, R.M., Lockfeld, A., Squillace, K.M., & Contel, N.R. (1981). Drug-environment interaction: context dependency of cocaine-induced behavioral sensitization. Life Science, 28, 755-760.
98. Post, R.M., & Weiss, S.R. (1996). A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Molecular Neurobiology, 13, 33-60.
99. Post, R.M., & Weiss, S.R. (2004). Convergences in course of illness and treatments of the epilepsies and recurrent affective disorders. Clinical EEG Neuroscience, 35, 14-24.
100. Rainnie, D.G., Asprodini, E.K., & Shinnick, G.P. (1992). Kindling-induced long-lasting changes in synaptic transmission in the basolateral amygdala. Journal of Neurophysiology, 67, 443-454.
101. Rao, J.S., Bazinet, R.P., Rapoport, S.I., & Lee, H.J. (2007). Chronic treatment of rats with sodium valproate downregulates frontal cortex NF-kappaB DNA binding activity and COX-2 mRNA. Bipolar Disorders, 9, 513-520.
102. Rosen, J.B., Cain, C.J., Weiss, S.R., & Post, R.M. (1992). Alterations in mRNA of enkephalin, dynorphin and thyrotropin releasing hormone during amygdala kindling: an in situ hybridization study. Brain Research & Molecular Brain Research, 15, 247-255.
103. Roy Chengappa, K.N., Schwarzman, L.K., Hulihan, J.F., Xiang, J., & Rosenthal, N.R. (2006). Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: A randomized, placebocontrolled trial. Journal of Clinical Psychiatry, 67, 1698-1706.
104. Roy-Byrne, P.P., Post, R.M., Uhde, T.W., Porcu, T., & Davis, D. (1985). The longitudinal course of recurrent affective illness: Life chart data from research patients at the NIMH. Acta Psychiatrica Scandinavica Supplementum, 317, 1-34.
105. Sander, J.W., Hart, Y.M., Trimble, M.R., & Shorvon, S.D. (1991). Vigabatrin and psychosis. Journal of Neurology, Neurosurgery & Psychiatry, 54, 435-439.
106. Schaffer, A., Zuker, P., & Levitt, A. (2006). Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression. Journal of Affective Disorder, 96, 95-99.
107. Shaltiel, G., Shamir, A., Shapiro, J., Ding, D., Dalton, E., Bialer, M. et al. (2004). Valproate decreases inositol biosynthesis. Biological Psychiatry, 56, 868-874.
108. Singh, V., Muzina, D.J., & Calabrese, J.R. (2005). Anticonvulsants in bipolar disorder. Psychiatric Clinics of North America, 28, 301-323.
109. Small, J.G., Klapper, M.H., Milstein, V., Marhenke, J.D., & Small, I.F. (1996). Comparison of therapeutic modalities for mania. Psychopharmacological Bulletin, 32, 623-627.
110. Smith, L.A., Cornelius, V., Warnock, A., Bell, A., & Young, A.H. (2007). Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: A systematic review of randomized controlled trials. Bipolar Disorders, 9, 394-412.
111. Smith, M.A., Makino, S., Kvetnansky, R., & Post, R.M. (1995). Effects of stress on neurotrophic factor expression in the rat brain. Annals of the New York Academy of Sciences, 771, 234-239.
112. Sokomba, E.N., Patsalos, P.N., Lolin, Y.I., & Curzon, G. (1988). Concurrent monitoring of central carbamazepine and transmitter amine metabolism and motor activity in individual unrestrained rats using repetitive withdrawal of cerebrospinal fluid. Neuropharmacology, 27, 409-415.
113. Southam, E., Kirby, D., Higgins, G.A., & Hagan, R.M. (1998). Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats. European Journal of Pharmacology, 358, 19-24.
114. Suppes, T., Chisholm, K.A., Dhavale, D., Frye, M., Altshuler, L.L., McElroy, S.L. et al. (2002). Tiagabine in treatment refractory bipolar disorder: A clinical case series. Bipolar Disorders, 4, 283-289.
115. Swann, A.C., Bowden, C.L., Morris, D., Calabrese, J.R., Petty, F., Small, J. et al. (1997). Depression during mania. Treatment response to lithium or divalproex. Archives of General Psychiatry, 54, 37-42.
116. Tohen, M., Vieta, E., Goodwin, G.M., Sun, B., Amsterdam, J.D., Banov, M. et al. (2008). Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: A randomized, 12-week, double-blind study. Journal of Clinical Psychiatry, 69, 1776-1789.
117. 2+-stimulated, release of corticotropin-releasing hormone from the rat hypothalamus. Psychopharmacology (Berl), 188, 386-392.
118. Turner, W.J. (1967). The usefulness of diphenylhydantoin in treatment of non-epileptic emotional disorders. International Journal of Neuropsychiatry, 3 (Suppl.), 20.
119. Vaden, D.L., Ding, D., Peterson, B., & Greenberg, M.L. (2001). Lithium and valproate decrease inositol mass and increase expression of the yeast ino1 and ino2 genes for inositol biosynthesis. Journal of Biological Chemistry, 276, 15466-15471.
120. van Calker, D., & Belmaker, R.H. (2000). The high affinity inositol transport system - implications for the pathophysiology and treatment of bipolar disorder. Bipolar Disorder, 2, 102-107.
121. Van der Loos, M., Nolen, W.A., & Vieta, E. (2007). Lamotrigine as add-on to lithium in bipolar depression. Bipolar Disorder, 9(Suppl. 1), 107.
122. Vasudev, K., Goswami, U., & Kohli, K. (2000). Carbamazepine and valproate monotherapy: Feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology (Berl), 150, 15-23.
123. Vieta, E., Manuel, G.J., Martinez-Aran, A., Comes, M., Verger, K., Masramon, X. et al. (2006). A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. Journal of Clinical Psychiatry, 67, 473-477.
124. Wagner, K.D., Kowatch, R.A., Emslie, G.J., Findling, R.L., Wilens, T.E., McCague, K. et al. (2006). A doubleblind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. American Journal of Psychiatry, 163, 1179-1186.
125. Walden, J., Altrup, U., Reith, H., & Speckmann, E.J. (1993). Effects of valproate on early and late potassium currents of single neurons. European Neuropsychopharmacology, 3, 137-141.
126. Waldman, I.D., Robinson, B.F., & Feigon, S.A. (1997). Linkage disequilibrium between the dopamine transporter gene (DAT1) and bipolar disorder: Extending the transmission disequilibrium test (TDT) to examine genetic heterogeneity. Genetic Epidemiology, 14, 699-704.
127. Wang, J.F., Bown, C.D., Chen, B., & Young, L.T. (2001). Identification of mood stabilizer-regulated genes by differential-display PCR. International Journal of Neuropsychopharmacology, 4, 65-74.
128. Wang, P.W., Santosa, C., Schumacher, M., Winsberg, M.E., Strong, C., & Ketter, T.A. (2002). Gabapentin augmentation therapy in bipolar depression. Bipolar Disorders, 4, 296-301.
129. Watson, S., Gallagher, P., Ritchie, J.C., Ferrier, I.N., & Young, A.H. (2004). Hypothalamic-pituitary-adrenal axis function in patients with bipolar disorder. British Journal of Psychiatry, 184, 496-502.
130. Wegerer, J.V., Hesslinger, B., Berger, M., & Walden, J. (1997). A calcium antagonistic effect of the new antiepileptic drug lamotrigine. European Neuropsychopharmacology, 7, 77-81.
131. Whitton, P.S., Oreskovic, D., Jernej, B., & Bulat, M. (1985). Effect of valproic acid on 5-hydroxytryptamine turnover in mouse brain. Journal of Pharmacy and Pharmacology, 37, 199-200.
132. Williams, R.S., Cheng, L., Mudge, A.W., & Harwood, A.J. (2002). A common mechanism of action for three mood-stabilizing drugs. Nature, 417, 292-295.
133. Wilson, M.S., & Findling, R.L. (2007). Zonisamide for bipolar depression. Expert Opinions in Pharmacotherapy, 8, 111-113.
134. +-ATPase in mouse brain synaptosomes. Journal of Neurochemistry, 52, 1042-1049.
135. Yatham, L.N., Liddle, P.F., Lam, R.W., Shiah, I.S., Lane, C., Stoessl, A.J. et al. (2002). PET study of the effects of valproate on dopamine D(2) receptors in neuroleptic- and mood-stabilizer-naive patients with nonpsychotic mania. American Journal of Psychiatry, 159, 1718-1723.
136. Yildiz, A., Guleryuz, S., Ankerst, D.P., Ongur, D., & Renshaw, P.F. (2008). Protein kinase C inhibition in the treatment of mania: A double-blind, placebo-controlled trial of tamoxifen. Archives of General Psychiatry, 65, 255-263.
137. Young, A.H., Geddes, J.R., Macritchie, K., Rao, S.N., & Vasudev, A. (2006a). Tiagabine in the maintenance treatment of bipolar disorders. Cochrane Database Systematic Reviews, 3: CD005173.
138. Young, A.H., Geddes, J.R., Macritchie, K., Rao, S.N., Watson, S., & Vasudev, A. (2006b). Tiagabine in the treatment of acute affective episodes in bipolar disorder: Efficacy and acceptability. Cochrane Database of Systematic Reviews, 3:CD004694.
139. Zajecka, J.M., Weisler, R., Sachs, G., Swann, A.C., Wozniak, P., & Sommerville, K.W. (2002). A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. Journal of Clinical Psychiatry, 63, 1148-1155.
140. Zarate, C.A., Jr., Singh, J., & Manji, H.K. (2006). Cellular plasticity cascades: Targets for the development of novel therapeutics for bipolar disorder. Biological Psychiatry, 59, 1006-1020.